Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay
Synonyms |
|
||||||||
Cerner Name |
|||||||||
Clinical Info |
The presence of MOG antibodies in AQP4 antibody negative individuals can help differentiate between multiple sclerosis (MS) and non-MS demyelinating diseases and aid in clinical management decisions. |
||||||||
Specimen Sources |
Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous |
||||||||
Specimen Types |
Blood |
||||||||
Container |
Red Top Tube |
||||||||
Collection Instructions |
Container/Tube: Red top tube |
||||||||
Specimen Volume |
2 mL serum ( 1.0 mL mL) |
||||||||
Transport Instructions |
Refrigerated |
||||||||
Specimen Stability |
Room temperature: 7 Days |
||||||||
Methodology |
Cell-based Immunofluorescence Assay |
||||||||
Days Performed |
TAT: 5-9 Days |
||||||||
Performing Laboratory |
Quest Diagnostics Nichols institute |
||||||||
CPT |
86362 |
||||||||
PDM |
1959033 |
||||||||
Only Orderable at Locations: |
Orderable Everywhere |
||||||||
Results |
|
||||||||
Result InterpretationMOG Ab CBA, Serum Negative his test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. |
|||||||||
Forms |
|